Actively Recruiting
Phase IIa Open-Label Study Evaluating ICG318 CAR-T Therapy for Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Led by iCell Gene Therapeutics · Updated on 2026-09-17
20
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and preliminary effects of a single infusion of ICG318 in people with refractory Systemic Lupus Erythematosus SLE, with or without Lupus Nephritis LN. SLE is a chronic autoimmune disease affecting multiple organs, and LN is a severe form of SLE affecting the kidneys. This Phase IIa open-label, single-arm study focuses on patients who have not responded adequately to prior therapies. Participants will first undergo a lymphodepletion treatment and then receive a single infusion of ICG318, an investigational chimeric antigen receptor CAR therapy designed to target specific B cells and plasma cells involved in SLE. The study includes an initial safety run-in followed by dose expansion to assess the recommended Phase 2 dose. The treatment involves a biologic drug infusion. During the study, participants will be closely monitored for adverse events up to one year after infusion. Researchers will measure disease activity, remission rates, kidney function, autoantibody levels, and immune cell recovery through blood tests, kidney biopsies, and other assessments. The total duration of participation includes treatment and follow-up evaluations extending to one year to understand safety and clinical responses.
CONDITIONS
Brief Title
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Research Team
A
Adam Chowdhury, MD, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here